The US Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...

Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director ...

Almirall (BME: ALM), the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...

Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. A calculation from the Medical Council shows that out ...

According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...